Interferon-α or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation

To the editor: We report here the clinical outcome for 2 chronic myeloid leukemia (CML) patients who acquired the T315I mutation while on imatinib, both of whom were treated successfully, one with recombinant interferon-alpha (rIFN) and the other with semisynthetic homoharringtonine (HHT). Patient